Research progress in m⁶A methylation modification in the treatment of hepatocellular carcinoma

Abstract

The long-term survival rate of patients with hepatocellular carcinoma （HCC） is poor， and drug efficacy is an important factor affecting clinical prognosis. N6-methyladenosine （m6A） modification is the most abundant modification in eukaryotic RNA， which can affect the occurrence and development of HCC and drug efficacy by regulating cancer-related biological functions. However， the role of m6A modification in HCC drug treatment has not been fully elucidated. Therefore， the biological functions of different regulatory members of the m6A modification process （methyltransferase， demethyltransferase and binding protein） in HCC drug treatment were illustrated， proposing that regulatory members of the m6A modification process can be used as biomarkers for HCC prognosis evaluation and have the potential to become therapeutic targets and providing novel insights for HCC precision medicine.

Keywords

• hepatocellular carcinoma|m⁶a modification|drug|systemic treatment